News|Videos|July 25, 2024
Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis
The panel identifies and discusses the unmet needs of patients with mild to moderate multiple sclerosis (MS), highlighting areas where current treatment options and management strategies fall short in addressing the unique challenges faced by this patient population.
Advertisement
Episodes in this series
- What are unmet needs for patients with mild or moderate MS?
- Diagnostic uncertainty in the mild disease
- Monitoring for subtle progression in these patients
- Considering invisible symptoms
Advertisement
Related to this article
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Tonic motor activation therapy was associated with reductions in RLS severity, along with tolerable reductions in dopamine agonist dosing, in adults with medication-refractory RLS.
A migraine forecasting model achieved 91% precision using app data, but the study did not test whether next-day predictions improve care.
The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to close the gap for underserved patients.
In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.
Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
2
From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026
3
Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms
4
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
5